J. B. Chemicals & Pharmaceuticals Limited
Momentum (86/100) does the heavy lifting; financial trend (5/100) is the drag.
ExpensiveOvervaluedJ. B. Chemicals & Pharmaceuticals Limited earns a Sell from StocksWizard, with a blended score of 44/100. On 50.2x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 4% below its 52-week high of ₹2,506 and 47% above the low of ₹1,638.82. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹2,258.22 implies about 6% downside across 9 analysts. It clears 8 of 13 investability checks, with durability 71, valuation 30 and momentum 86 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,300.57.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-3.87% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell44Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 18.7%
- Pass: Low debt (D/E < 0.5): 0.00x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -5%
- Fail: Earnings growing: -31%
- Pass: Net margin ≥ 10%: 17.1%
- Pass: Current ratio > 1.5: 4.92
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 28.91
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter49.2%
- Institutions30.8%
- Public & other20.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (18.7%).
- Lightly leveraged balance sheet.
- Healthy profit margin (17.1%).
- Financially solid — Altman Z 28.91.
Bear case
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
- Trades ~33% above our estimated fair value.
About J. B. Chemicals & Pharmaceuticals Limited
J. B. Chemicals & Pharmaceuticals Limited manufactures and distributes pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients across India and international markets.
J. B. Chemicals & Pharmaceuticals Limited — frequently asked questions
Is J. B. Chemicals & Pharmaceuticals Limited a buy, hold or sell?
StocksWizard currently rates J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM) a Sell, based on a blended score of 44/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is J. B. Chemicals & Pharmaceuticals Limited's fair value?
Our blended DCF and relative-valuation model estimates J. B. Chemicals & Pharmaceuticals Limited's fair value at about ₹1,625.71, versus a current price of ₹2,408.9 — roughly 33% downside. On that basis the stock looks overvalued by 33%.
Is J. B. Chemicals & Pharmaceuticals Limited financially healthy?
J. B. Chemicals & Pharmaceuticals Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has J. B. Chemicals & Pharmaceuticals Limited's share price performed?
J. B. Chemicals & Pharmaceuticals Limited is up 18% over three months, and last traded at ₹2,408.9. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.